225. Congenital nephrogenic diabetes insipidus
12 clinical trials,   45 drugs   (DrugBank: 17 drugs),   30 drug target genes,   63 drug target pathways

Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-001591-30-DK
(EUCTR)
06/11/201709/03/2017 Treatment of congenital nephrogenic diabetes insipidus with riociguat or sildenafil Treatment of congenital nephrogenic diabetes insipidus with a guanylate cyclase stimulator, riociguat or a phosphodiesterase type 5 inhibitor, sildenafil Nephrogenic diabetes insipidus because of AVP2R-mutation
MedDRA version: 20.0;Level: LLT;Classification code 10012626;Term: Diabetes nephrogenic (excludes glycosuria);System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Odense University HospitalNULLNot Recruiting Female: no
Male: yes
2Phase 2Denmark